Abstract: Multiple myeloma, an incurable clonal plasma cell dysplasia, is the second most common hematological malignancy. Standardized diagnosis and treatment are crucial for prolonging the survival of myeloma patients and improving the quality of their lives. There is a need to develop a diagnosis and treatment pathway to match the unique economic, cultural, regional characteristics and new drugs available in Guangxi. Therefore, the Control Center of Medical Quality of Guangxi Hematology and the Guangxi Plasma Cell Disease Collaboration Group have, based on the guidelines and expert consensus at home and abroad, developed this clinical diagnosis and treatment pathway.